Cantor Fitzgerald Reiterates Overweight Rating on Aardvark Therapeutics Inc (AARD)

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $50.00 price target on Aardvark Therapeutics Inc (NASDAQ: AARD).

The analyst commented, "With just a $200M mkt cap, AARD offers a couple of ways to win big, or if both programs succeed - win VERY big. As 2026 data draws near, we expect shares to appreciate considering a very asymmetric risk-reward profile at current levels."

For an analyst ratings summary and ratings history on Aardvark Therapeutics Inc click here. For more ratings news on Aardvark Therapeutics Inc click here.

Shares of Aardvark Therapeutics Inc closed at $9.67 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Darling Ingredients receives US patent for blood glucose collagen peptide
• Redwire Defense wins $15.9M Army contract for drone systems